PMID- 17610317
OWN - NLM
STAT- MEDLINE
DCOM- 20071127
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 34
IP  - 8
DP  - 2007 Aug
TI  - Changes of clinical response and bone biochemical markers in patients with 
      ankylosing spondylitis taking etanercept.
PG  - 1753-9
AB  - OBJECTIVE: Tumor necrosis factor-alpha has a prominent role in the inflammatory 
      process and bone resorption in patients with ankylosing spondylitis (AS). We 
      evaluated the markers of clinical efficacy and bone biochemical changes in Korean 
      patients with AS treated with etanercept therapy. METHODS: Serum samples from 26 
      patients receiving etanercept for refractory AS were obtained at baseline and 12 
      weeks after treatment. Clinical measures and serum levels of transforming growth 
      factor-Beta (TGF-Beta), matrix metalloproteinase-3 (MMP-3), macrophage-colony 
      stimulating factor (M-CSF), bone-specific alkaline phosphatase (BALP), 
      osteocalcin, C-telopeptide (CTX), receptor activator of nuclear factor-kB ligand 
      (RANKL), and osteoprotegerin (OPG) were measured at each timepoint. RESULTS: 
      Significant improvement of the Bath AS Disease Activity Index (BASDAI) and 
      Functional Index (BASFI) was achieved after 12 weeks (p < 0.001). ASsessments in 
      Ankylosing Spondylitis Working Group (ASAS) 20 criteria were achieved by 22 
      patients (84.6%) after 12 weeks' treatment. ASAS 50 and 70 were achieved by 10 
      (38.5%) and 7 patients (26.9%). Serum levels of BALP and osteocalcin were 
      significantly increased after 12 weeks of treatment (p < 0.05). Serum levels of 
      CTX were not changed after treatment. Serum levels of TGF-Beta, MMP-3, and M-CSF 
      were significantly decreased after 12 weeks of treatment (p < 0.05). Serum levels 
      of OPG and RANKL were not changed. Change of MMP-3 had a high correlation 
      coefficient with changes of C-reactive protein (CRP) and erythrocyte 
      sedimentation rate (ESR) upon etanercept treatment (CRP, r = 0.446, p = 0.022; 
      ESR, r = 0.449, p = 0.021). CONCLUSION: In patients with AS, etanercept therapy 
      may be effective for reducing disease activity and improving bone biochemical 
      markers. MMP-3 may be a useful biomarker for monitoring etanercept therapy.
FAU - Woo, Jin-Hyun
AU  - Woo JH
AD  - Division of Rheumatology, the Hospital for Rheumatic Diseases, The Institute of 
      Rheumatism, Hanyang University, Seol, Korea.
FAU - Lee, Hyun-Joo
AU  - Lee HJ
FAU - Sung, Il-Hoon
AU  - Sung IH
FAU - Kim, Tae-Hwan
AU  - Kim TH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20070615
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Collagen Type I)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Osteoprotegerin)
RN  - 0 (Peptides)
RN  - 0 (RANK Ligand)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (TNFSF11 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (collagen type I trimeric cross-linked peptide)
RN  - 104982-03-8 (Osteocalcin)
RN  - 81627-83-0 (Macrophage Colony-Stimulating Factor)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - OP401G7OJC (Etanercept)
SB  - IM
CIN - J Rheumatol. 2007 Aug;34(8):1647-9. PMID: 17696283
MH  - Adult
MH  - Alkaline Phosphatase/blood
MH  - Antirheumatic Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Collagen Type I/blood
MH  - Dose-Response Relationship, Drug
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Korea
MH  - Macrophage Colony-Stimulating Factor/blood
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Osteocalcin/*blood
MH  - Osteoprotegerin/blood
MH  - Peptides/blood
MH  - RANK Ligand/blood
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/blood/*drug therapy/*physiopathology
MH  - Transforming Growth Factor beta/blood
EDAT- 2007/07/05 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/07/05 09:00
PHST- 2007/07/05 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/07/05 09:00 [entrez]
AID - 07/13/0616 [pii]
PST - ppublish
SO  - J Rheumatol. 2007 Aug;34(8):1753-9. Epub 2007 Jun 15.